# The Biotech Patent Cliff & M&A - Week of June 5, 2026: Pfizer's $10.5B Innovent Deal Headlines a Dealmaking Sprint

> Pharma and biotech newsletter for the week ending Friday, June 5, 2026. Pfizer's up-to-$10.5B Innovent oncology collaboration headlines a dealmaking sprint, Lilly fires off four licensing deals in five days, and ASCO derisks the SMID takeout targets while Eli Lilly's CEO frames GLP-1 dominance on The Prof G Pod.


## The Biotech Patent Cliff & M&A

### Week ending Friday, June 5, 2026: Pfizer's $10.5B Innovent Deal Headlines a Dealmaking Sprint

---

```request-access
variant: ghost
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

The operators got busy this week even as the commentary stayed light. The clearest investor read came from Eli Lilly CEO David Ricks on [The Prof G Pod](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOik7YItzZZPaf0hm6Zz6vktBIJM3KqAojJEYh4flV-2FrG8Cpj4ZZdnfL7TUfFBcu7v93SYNDpTwSE0aQlqgyzmlrdFQazsPf0e-2BIOOaMvzL44g-3D-3DyWMz_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUN5Wsh-2BP6cwpcgyLk48An21tWyHHfMm-2FPZxaqqfKG56fhhrm68VOHehunwpr4uBUpDCHArGuFWcNIs3QZKreiK0JyKA7OUFlR0R8moMneEcBMfl1KhIlP7H6T9DANbeLZDqWvWhHEIyLQFzTwkptT0E-2B4rMgT4LHMAt6MX-2B24Rtw-3D-3D), so this issue leans on what the companies actually did: term sheets, FDA letters, and an ASCO data dump.

**TL;DR**

- **Pfizer wrote the biggest check of the week**, up to $10.5B for 12 early-stage Innovent oncology programs ($650M upfront), the clearest sign yet that a cliff-exposed buyer is filling the Eliquis hole with bolt-on biology, not a megamerger.
- **Lilly is deploying anyway**, with four licensing deals in five days (Haisco, Hanmi, Ascidian, Camurus) plus two pending heme acquisitions. The firepower-rich buyer with no near-term cliff is still the most aggressive shopper.
- **ASCO handed the SMID targets their valuations.** Revolution Medicines (+11%) and Summit (+5%) both posted plenary survival wins. The takeout candidates just got more expensive and more derisked at the same time.

## What's New

**1. Pfizer's $10.5B Innovent collaboration, the cliff-fill blueprint.** Pfizer and Innovent Biologics struck a global licensing and collaboration deal across 12 early-stage oncology programs, antibody-drug conjugates and multi-specific antibodies. Innovent gets $650M upfront and is eligible for up to $9.85B in development, regulatory and commercial milestones, plus up to double-digit royalties; the structure mixes outright ex-China licenses with co-develop and co-commercialize arrangements in the US and Europe. The deal is expected to close in Q3. *Why it moves the thesis:* this is exactly the playbook the bull case demands of Pfizer, buy early-stage optionality cheaply rather than overpay for a de-risked single asset. It's oncology pipeline depth to backfill the Eliquis LOE without bloating the balance sheet.

**2. Lilly's five-day licensing sprint.** The firepower buyer with the least urgent cliff was the busiest dealmaker: a drug-discovery collaboration with Haisco worth up to $3.05B ($87M upfront and near-term, up to $2.97B milestones); exclusive ex-Korea rights to Hanmi's long-acting GLP-2 sonefpeglutide ($75M upfront, up to $1.185B milestones); RNA exon-editing rights from Ascidian for kidney targets (up to $1.9B); and an option exercise to add amylin receptor agonists to the Camurus long-acting cardiometabolic deal (up to $290M development and regulatory plus $580M sales milestones). Lilly also flagged its pending acquisitions of Ajax Therapeutics and Kelonia Therapeutics in hematology. *Why it matters:* Lilly isn't buying to plug a hole, it's buying to widen an already-dominant cardiometabolic and oncology lead. That's the supercycle in microcosm.

**3. ASCO derisked two of our top takeout targets.** **Revolution Medicines (RVMD)** posted full Phase 3 RASolute 302 data for oral RAS(ON) inhibitor daraxonrasib in second-line metastatic pancreatic cancer: a **60% reduction in the risk of death**, median OS **13.2 months vs ~6.6 months** on chemo, presented at the ASCO plenary with simultaneous NEJM publication. Shares jumped ~11% to $174.50; sell-side piled on (Oppenheimer and H.C. Wainwright both to $195, RBC to $182). **Summit (SMMT)** delivered HARMONi-6 overall-survival data for ivonescimab vs tislelizumab in first-line squamous NSCLC, a **34% reduction in risk of death**, presented at the ASCO plenary and published in The Lancet, plus a 70.8% ORR in a separate Phase 2 colorectal cohort; the stock rose 5% to $18.41. *Why it matters:* both are now harder to buy on the cheap, but the strategic logic for a large-cap acquirer just strengthened.

**4. Merck quietly fortified the Keytruda moat.** Two items bear directly on Merck's biggest cliff. The Moderna-partnered mRNA cancer vaccine intismeran autogene posted **5-year KEYNOTE-942 melanoma data: a 49% reduction in recurrence-or-death and a 59% reduction in distant-metastasis-or-death** on top of Keytruda. And calderasib, an oral KRAS G12C inhibitor, won FDA Breakthrough Therapy designation in first-line KRAS-G12C/PD-L1+ NSCLC in combination with Keytruda. *Why it matters:* the IV-to-subcutaneous defense gets the headlines, but extending Keytruda into combination franchises with their own IP runways is the more durable answer to the 2028 biologic cliff.

**5. The operator clip, Lilly's Ricks on GLP-1 dominance.** David Ricks, Chair and CEO of Eli Lilly, on [The Prof G Pod](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOik7YItzZZPaf0hm6Zz6vktBIJM3KqAojJEYh4flV-2FrG8Cpj4ZZdnfL7TUfFBcu7v93SYNDpTwSE0aQlqgyzmlrdFQazsPf0e-2BIOOaMvzL44g-3D-3DyWMz_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUN5Wsh-2BP6cwpcgyLk48An21tWyHHfMm-2FPZxaqqfKG56fhhrm68VOHehunwpr4uBUpDCHArGuFWcNIs3QZKreiK0JyKA7OUFlR0R8moMneEcBMfl1KhIlP7H6T9DANbeLZDqWvWhHEIyLQFzTwkptT0E-2B4rMgT4LHMAt6MX-2B24Rtw-3D-3D): *"products like Zepbound or our new one Foundeo, they work. People lose weight. Almost everybody who takes them loses weight… obesity is kind of like a nodal health condition for more than 200 chronic diseases."* *Why it matters:* Ricks naming a new product ("Foundeo") alongside Zepbound underscores why Lilly feels no pressure to do obesity M&A, and meanwhile Novo just launched the oral Wegovy pill in the UAE (~17% weight loss over 64 weeks), its first market outside the US.

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## The Debate

**The supercycle bull:** This week is the thesis in action. A cliff-exposed buyer (Pfizer) and a firepower buyer (Lilly) deployed real capital into early-stage biology, ASCO derisked the next generation of acquisition targets, and the FDA issued [draft guidance to accelerate cell and gene therapy submissions](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NnOqKlXMknrnFC04y62-2Fcbxk-2BvQ8myoIhw66-2FEWm-2B6A9VJ7uaRTgZk5Yyr8bo6RcPmvPZPfgdgv8DKZ-2FQAr20Q29L2gk2gniYsIvIamuMhHs3JHvV58lxOfFfq6lpq-2For8-2B0vuFmk7qULf4brCDNDIPkDjCG9kEuyQ-2F-2B0YBgOZUt9-za_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUN5Wsh-2BP6cwpcgyLk48An21tWyHHfMm-2FPZxaqqfKG56erJiLUSjcvovYLOKSsVlUGeN42ERUeJA7PcBCkCLY5Inx6E9rDB-2Bh8cO1mGGJF883BlVkOZUp4rQmSaNX5qXNvyCqE428gCNNmCVdEV9rhpEcdCVFlQGGHcSnaEXR2evg-3D-3D). Targets are validated, capital is moving, and the regulator is leaning in. Buy the buyers and the best-in-class SMID assets.

**The cliff-erosion bear:** Look closer and almost none of this week's deals were acquisitions, they were licensing deals and milestones-heavy options. That's what you do when you're nervous about valuations and the IRA. ASCO wins make the obvious targets pricier, not cheaper, and AstraZeneca's [CARES program missed its primary endpoint](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7Nnh4jopFMlqPujNCEOhNd36bqTGUNyfAYUwzK2ZzHfhJX4Jn0aaW33mV7FaMVa2NSUeLPm-2FxQlbWA7uaZAnqKH14s2D3BvHTh54T2vIBaN2SSLJfoA4qURadC7Sf9fUX2mK-2BZHNJBp43mWZ1c94mSpTLWHdKvi9Ef7k4QH4MBAfBXOb5DC4P6NW8XyrDDopWbhbx0zr-2BL0J-2BslMQKeWf5OYSX31vH3OVD3nigO6wgCpQcVaO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUN5Wsh-2BP6cwpcgyLk48An21tWyHHfMm-2FPZxaqqfKG56ZSjTFlxPK-2FyMs9HdeD47Cf3y-2FmsA4nHDnJ-2BiksdsJL2Uizxv6spULF9oqXtgrqOTBZCbLwZkb4-2BvyGSUj7SVM9N1Z8hTocemXZc47tjUosV-2F7qE0-2BEt5YoU8yr-2BAHH9bQ-3D-3D) in the overall AL amyloidosis population (kappa subgroup salvage only), a reminder that late-stage biology still breaks. And the silence on FTC posture and IRA pill-penalty mechanics isn't comfort, it's an unpriced overhang.

**My take:** The bears are right that this was a licensing week, not an M&A week, but that's a tell, not a refutation. When the strategics are this willing to pay $650M to $3B upfront for Phase 1 assets, the appetite for the de-risked Phase 3 names (RVMD, SMMT) is only building. The ASCO pop in those two is the market front-running a bid, not pricing one out. I'd rather own the validated target into a richer print than wait for a "cheap" entry that the data just erased.

## Stocks in Play

| Ticker | Bull case | Bear case | Next catalyst / number to watch |
| --- | --- | --- | --- |
| **PFE** | $10.5B Innovent deal builds oncology depth cheaply ahead of Eliquis LOE; ASCO wins (Lorbrena 7-yr, Braftovi, Talzenna) show base-business durability | Still a licensing patch, not a franchise; the cliff math is unforgiving | Innovent deal close (Q3); pipeline conversion of the 12 programs |
| **LLY** | Four BD deals in a week plus pending Ajax/Kelonia; GLP-1 lead extending ("Foundeo"); Retevmo adjuvant NSCLC EFS −83% | Valuation prices perfection; no cliff means every deal must clear a high bar | EHA (June 11–14) BRUIN CLL-322 readout; obesity competitive data |
| **MRK** | Keytruda moat extended via intismeran (−49%/−59%) and calderasib BTD | 2028 biologic cliff still the dominant risk; subcutaneous defense unproven commercially | Subcutaneous Keytruda uptake; calderasib registrational timing |
| **RVMD** | Daraxonrasib −60% risk of death in 2L PDAC, NEJM, PTs to $195; premier RAS franchise | ASCO pop means pricier takeout; pan-RAS competition (ERAS-0015) | NDA submission; RASolve 301 / RASolute 303/304/309 reads |
| **SMMT** | Ivonescimab HARMONi-6 OS −34%, Lancet; PD-(L)1xVEGF class leader | China-data dependence; needs ex-China confirmatory wins | US/global confirmatory NSCLC data; partnership/takeout chatter |
| **BMY** | Mezigdomide −52% in myeloma (mPFS 18 vs 8.3 mo); pumitamig plus iza-bren ADCs | Revlimid/Eliquis erosion still the headline; mean PT only ~$63 | Pumitamig ROSETTA Lung-02 Phase 3; mezigdomide filing |
| **JNJ** | Deep ASCO/heme/immunology slate (TECVAYLI −71%, RYBREVANT mOS ~41 mo) cushions Stelara biosimilars | Stelara erosion accelerating; no splashy deal this week | Stelara biosimilar trajectory; nipocalimab Phase 3 lupus/Sjogren's |
| **AZN** | Imfinzi NMIBC approval plus EMERALD-3 HCC win (−30%); SERENA-6 ctDNA | CARES (anselamimab) missed primary endpoint, an Alexion setback | SERENA-6 OS maturation; oncology filing cadence |

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## Read-Throughs

- **Takeout targets:** ASCO turned RVMD and SMMT from "story stocks" into "validated assets." Expect the rumor mill to reactivate, a derisked oral RAS franchise (RVMD) and a PD-(L)1xVEGF bispecific (SMMT) are exactly what cliff-exposed large caps say they want.
- **The PD-(L)1xVEGF arms race is real:** Summit's ivonescimab OS win and the BMY/BioNTech pumitamig Phase 2 (ORR 63.6% non-squamous / 72.7% squamous) put the whole bispecific class in play. Watch who else (Merck, Pfizer) needs to buy in.
- **SMID sentiment / XBI:** IBB rose 0.3% even on a down healthcare tape. Plenary-stage wins plus a friendlier FDA cell and gene posture is the cocktail SMID sentiment has been waiting for.
- **Bankers and CROs:** A week this thick with cross-border licensing (Innovent, Haisco, Hanmi, all China and Korea-originated) signals the BD pipes are wide open. Good for advisory fees; watch for FTC and CFIUS commentary that hasn't yet surfaced.

## What Changed vs Last Week

This is the first issue of *The Biotech Patent Cliff & M&A* in this format, so there's no prior week to mark to. Two things to file for next Friday: whether the Pfizer/Innovent and Lilly deals draw any FTC or CFIUS noise (no antitrust pushback has surfaced yet), and whether the RVMD and SMMT ASCO pops convert into actual takeout chatter or fade. We'll track both.

```request-access
variant: banner
heading: Run your own corpus.
description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage.
buttonText: Request access
```